Ardent Health Securities Suit Draws New Filings as Lead‑Plaintiff Deadline Nears
Multiple firms mobilize investors before March 9, targeting Ardent’s November 12 disclosures on receivables plus malpractice reserves.
Overview
- Robbins Geller joined Rosen, Bleichmar Fonti & Auld, and Glancy in soliciting ARDT investors to seek lead‑plaintiff status in Postiwala v. Ardent Health, Inc.
- The case is pending in the U.S. District Court for the Middle District of Tennessee under No. 3:26‑cv‑00022, with no class yet certified.
- Complaints allege Ardent touted history‑based collectability reviews while relying on a 180‑day reserving cliff that inflated receivables and deferred write‑offs.
- Ardent’s November 12, 2025 update disclosed a $43 million revenue reduction tied to a new revenue accounting system and a $54 million increase in professional liability reserves.
- Filings also cite a cut to 2025 EBITDA guidance and a stock drop of roughly one‑third, as well as claims that malpractice exposure in New Mexico outpaced insurance and reserves.